APPENDIX 2.

Summary of change from baseline in the ACR core set measures at Week 104 (intent-to-treat population).

	SJC, 66 Joint Count	TJC, 68 Joint Count	Patient Global VAS, mm	Physician Global VAS, mm	Patient Pain VAS, mm	CRP, mg/dl	ESR, mm/h	HAQ-DI
Placebo-MTX, n = 393
n	391	391	137	139	137	139	139	127
Mean	−3.5	−5.9	−33.2	−43.9	−25.6	−1.6346	−30.7	−0.50
SD	11.65	17.07	26.35	21.55	24.44	2.28001	22.26	0.612
Median	−2.0	−3.0	−33.0	−47.0	−28.0	−0.8890	−30.0	−0.50
Minimum-maximum	−58 to 43	−65 to 42	−89 to 29	−87 to 25	−78 to 45	−14.927 to 1.150	−108 to 30	−2.3 to 1.4
4 mg/kg tocilizumab-MTX, n = 399
n	399	399	228	229	228	231	231	218
Mean	−9.0	−13.6	−31.6	−49.1	−26.6	−1.6863	−35.4	−0.58
SD	10.76	16.53	27.05	20.33	25.39	2.20965	25.07	0.608
Median	−8.0	−13.0	−32.0	−50.0	−26.0	−1.0820	−32.0	−0.50
Minimum-maximum	−57 to 21	−68 to 35	−100 to 60	−94 to 22	−100 to 36	−12.240 to 5.140	−117 to 55	−3.0 to 1.1
8 mg/kg tocilizumab-MTX, n = 398
n	397	397	248	250	248	251	247	231
Mean	−11.3	−17.7	−33.9	−48.7	−28.9	−2.3068	−36.9	−0.61
SD	11.31	16.73	26.60	22.20	25.47	2.65256	23.39	0.661
Median	−10.0	−17.0	−32.5	−50.0	−27.0	−1.5400	−33.0	−0.50
Minimum-maximum	−62 to 48	−67 to 48	−95 to 39	−97 to 48	−96 to 34	−19.281 to 3.359	−114 to 57	−2.9 to 1.5

Last-observation-carried-forward was used for TJC and SJC; no imputation was used for missing HAQ score, CRP, ESR, and VAS assessments. All assessments were set to missing from the time a patient receives escape therapy, and only pre-escape therapy joint count assessments were carried forward. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire Disability Index; SJC: swollen joint count; TJC: tender joint count; VAS: visual analog scale; ACR: American College of Rheumatology; MTX: methotrexate.